![](/img/cover-not-exists.png)
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Jean-Michel Molina, Anthony LaMarca, Jaime Andrade-Villanueva, Bonaventura Clotet, Nathan Clumeck, Ya-Pei Liu, Lijie Zhong, Nicolas Margot, Andrew K Cheng, Steven L ChuckVolume:
12
Year:
2012
Language:
english
DOI:
10.1016/s1473-3099(11)70249-3
File:
PDF, 209 KB
english, 2012